Trading Signals: ADAP Stock Price Prediction and Forecast (Mon. Oct. 26, 2015 - Fri. May. 28, 2021)(Adaptimmune Therapeutics plc)
| ADAP latest price $6.3100 (-20.13%) ($6.2500 - $7.7000) on Fri. Oct. 16, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.78% (three month average) | RSI | 42 | Latest Price | $6.3100(-20.13%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADAP declines -4.6% a day on average for past five trading days. | Weekly Trend | ADAP declines -0.6% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support ADAP advance at 0% a week (0% probability) UNG(17%) SDY(16%) XLP(16%) XLRE(15%) IFRA(13%) | Factors Impacting ADAP price | ADAP will decline at least -2.89% in a week (0% probabilities). TIP(-14%) CEMB(-14%) BWX(-13%) BNDX(-13%) BND(-13%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.89% (StdDev 5.78%) | Hourly BBV | 0 () | Intraday Trend | -17.3% | | | |
|
1 - 5 Day Possible Target | $-10.77(-270.68%) | Resistance Level | $8.14 | 5 Day Moving Average | $7.94(-20.53%) | 10 Day Moving Average | $8.12(-22.29%) | 20 Day Moving Average | $8.14(-22.48%) | To recent high | -41.5% | To recent low | 0% | Market Cap | $976m | | | | Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |